Clinic Software← All companies
Raised$8.26 million
Employees16
LocationMissoula, MT
About
FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.
Product
- Value proposition
- AI-powered EV-Omics platform (EVO) enabling RNA and protein insights from blood to inform biomarker discovery, smarter trials, and personalized patient care.
- Target customers
- Biotech and pharma companies, diagnostic developers, clinical researchers
Founders
- Chris Booth, Ph.D.
- Sarjubhai Patel, Ph.D.
Categories
Products
EV-Omics (EVO) platformSPARCs enrichment technologyRNA and protein insights from blood
Key features
Enrichment of disease-associated extracellular vesicles (EVs)AI-enabled multi-omic analysisProteins and RNA profiling from bloodMolecular snapshots of diseaseSupport for discovery through clinical validationCustom data outputs and flexible engagement models
Technologies
EV-Omics (EVO)SPARCs technologyAI/multi-omics integrationExtracellular vesicle enrichment
Partnerships
Partner with FYR (from site)Collaborative approach for tailored study design
Investors
Sontag Innovation FundYuvaan Tiwari FoundationTwo Bear CapitalNational Cancer InstituteNational Science Foundation
News
- FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience - FYR Bio · 2025-09-24T14:27:14.000Z
- FYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma Trial - FYR Bio · 2025-11-19T16:46:28.000Z
- FYR lands funding to find new biomarkers for Parkinson's · 2025-09-26T16:52:43.000Z
- FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease - FYR Bio · 2025-04-29T13:12:21.000Z
- FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine - FYR Bio · 2025-10-09T14:14:26.000Z
- FYR Closes $8 Million Financing to Advance Blood... - BioSpace · 2025-09-25T00:00:00.000Z
